Trial Profile
Parallel, Group, Laboratory-Blinded, Single and Multiple-dose Pharmacokinetic Study of Ondansetron Administered as the Immediate-Release (Zofran) and Modified-Release (EUR1025) Formulations
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2017
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Nausea and vomiting
- Focus Pharmacokinetics
- Sponsors Eurand
- 29 Dec 2009 New trial record
- 17 Dec 2009 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.